Table 1 Current ongoing VISTA therapeutics (small molecule inhibitors and mAbs) in preclinical and clinical development
From: VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy
Intervention | Description | Target | Cancer type | Developed by | Phase | Identifiers | Location | Status |
|---|---|---|---|---|---|---|---|---|
Antibodies (Agonist) | ||||||||
 4C11 | mAb | VISTA | Asthma | Yale University | Preclinical | – | – | – |
 7G1 | mAb | VISTA | Psoriasis | University of Toronto | Preclinical | – | – | – |
Small molecule inhibitors | ||||||||
 AUPM-493 | small molecule | VISTA & VSIG-8 | Melanoma, and colon cancer | Aurigene, Inc | Preclinical | – | – | – |
 CA-170 | small molecules | VISTA & PD-L1/L2 | Advanced Solid Tumors or Lymphomas | Curis, Inc | Phase I | NCT02812875 | U.S.A | Completed |
 CA-170 | small molecules | VISTA & PD-L1/L2 | Lung cancer, Hodgkin lymphoma, head and neck/oral cavity cancer, and MSI-high cancer | Aurigene & Curis, Inc | Phase II | CTRI/2017/12/011026 | India | Terminated |
Blocking antibodies (Antagonist) | ||||||||
 PMC-309 | IgG1 mAb | VISTA | In vitro assays and multiple syngeneic mouse tumor models | PharmAbcine, Inc | Preclinical | – | – | – |
 KVA 12.1 | IgG1 mAb | VISTA | In vitro assays and multiple syngeneic mouse tumor models | Kineta, Inc | Preclinical | – | – | – |
 APX-201 | mAb | VISTA | In vitro assays and multiple syngeneic mouse tumor models | Apexigen, Inc | Preclinical | – | – | – |
 VTX-0811 | mAb | PSGL-1 | In vitro assays and multiple syngeneic mouse tumor models | Verseua, Inc | Preclinical | – | – | – |
 SNS-101 | IgG1 mAb | VISTA/PSGL-1 | In vitro assays and multiple syngeneic mouse tumor models | Sensei Bio, Inc | Preclinical | – | – | – |
 IMT-18 | mAb | VSIG-3 | In vitro assays and multiple syngeneic mouse tumor models | iOMx, Inc | Preclinical | – | – | – |
 BMS767 | mAb | VISTA | In vitro assays and multiple syngeneic mouse tumor models | Bristol-Myers Squibb, Inc | Preclinical | – | – | – |
 IGN-381 | mAb | VISTA | Hematological cancer and Solid tumors | Igenica Biotherapeutics, Inc | Preclinical | – | – | – |
 SG7 | mAb | VISTA/PSGL-1 & VSIG-3 | In vitro assays and multiple syngeneic mouse tumor models | Mehta et al | Preclinical | – | – | – |
 VSTB112 (JNJ-61610588) | IgG1 mAb | VISTA | Lung, pancreatic, head and neck, colorectal, and cervical cancers | ImmuNext/Janssen, Inc | Phase I | NCT02671955 | U.S.A | Terminated |
 CI-8993 (Onvatilima) | IgG1 mAb | VISTA | Advanced solid tumors | Curis, Inc | Phase I | NCT04475523 | U.S.A | Recruiting |
 W018 | mAb + Pembrolizumab | VISTA/PSGL-1 | Locally advanced or metastatic solid tumors | Pierre Fabre Medicament, Inc | Phase I | NCT04564417 | France&Spain | Recruiting |
 HMBD-002 | IgG4 mAb | VISTA/VSIG-3 & LRIG1 | Advanced solid tumors | Hummingbird Bioscience, Inc | Phase I/II | NCT05082610 | U.S.A | Recruiting |